TNFRSF17 and neuroblastoma: Other antigen targets that may be worthwhile exploring for CAR development includes GD-2 for neuroblastomas (42), CD20 (43), and CD22 for B cell lymphomas (44), BCMA (B cell maturation antigen) (45), and CD38 for multiple myeloma (46), CD23 for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (47), CD30 for Hodgkin’s lymphoma and anaplastic large cell lymphomas (48), CD33 for acute myeloid leukemias (49), EGFRvIII for glioblastomas (50) and PSCA (51) and PSMA (52) for prostate adenocarcinomas (Figure 1).